Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexicon

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

Novo Nordisk preps for speedy oral GLP-1 drug filing

Needs to compete with rival's fast-growing Trulicity

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

Sanofi reception

FDA adcomm split on Sanofi’s type 1 diabetes drug

Concerns rose after Zynquista-treated patients showed an eight-fold increase in DKA

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

- PMLiVE

As France protests, Sanofi takes axe to 670 jobs

Layoffs latest in restructuring programme

- PMLiVE

Zafgen shares tumble after FDA places hold on diabetes trial

Regulator concerns based on deaths with previous drug

- PMLiVE

CHMP backs Sanofi’s all-oral sleeping sickness drug

Sanofi's drug and others given green light by EMA committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links